Summary The cytoxicity of both intercalating (m-AMSA) and non-intercalating (VP16, VM26) topoisomerase II-targeting drugs is thought to occur via trapping DNA topoisomerase II on DNA in the form of cleavable complexes. First, analysis of cleavable complexes (detected as DNA double-strand breaks) by pulsed-field gel electrophoresis confirmed the correlation between cleavable complex formation and cytotoxicity of three topoisomerase-targeting drugs in HeLa S3 cells (the order of effects being VM26> m-AMSA>VP16). In contrast to many antineoplastic agents, hyperthermic treatments were found to protect cells against the toxicity of all three topoisomerase II drugs. Hyperthermia treatment does not alter drug accumulation but reduces the ability of the drug-topoisomerase II complex to form the cleavable complexes. Nuclear protein aggregation induced by heat at the sites of topoisomerase II-DNA interaction may explain such an effect. In thermotolerant cells, the toxic effects of VP16 but not m-AMSA were reduced. For both drugs, however, the status of thermotolerance did not affect cleavable complex formation by the drugs. Thus, protection against VP-16 toxicity seems not to be associated with heat-induced activation of the P-gp 170 pump or altered topoisomerase II-DNA interactions. Rather, a protective (heat shock protein mediated?) mechanism against non-intercalating topoisomerase II drugs seems to occur at a stage after DNA-drug interaction. Finally, heat treatment before topoisomerase II drug treatment reduced toxicity and cleavable complex formation in thermotolerant cells to about the same extent as in non-tolerant cells, consistent with the presumption of nuclear protein aggregation being responsible for this effect.
Hyperthermia is a powerful tool to enhance the cell killing effects of radiation (Konings, 1987) and many anti-neoplastic agents (Engelhardt, 1987) . However, heat pretreatment leads to a reduction in the toxic action of some drugs. Preheating causes resistance to daunorubicin (Mizuno et al., 1980) , doxorubicin (Rice and Hahn, 1987) and m-AMSA (Kampinga et al., 1989a) . Interestingly, the putative target of all these drugs is DNA topoisomerase II (Wang, 1985) .
It has been shown that the reduction in cytotoxicity of m-AMSA resulting from preheating cells is not due to heataltered drug permeability (Kampinga et al., 1989a) or to thermal inactivation of the topoisomerase II enzyme (Kampinga et al., 1989a; Warters and Barrows, 1994) . Reduced toxicity is accompanied by a reduction in topoisomerase II-mediated DNA breakage (cleavable complex formation) (Kampinga et al., 1989a) . Since the topoisomerase II inhibitors used in these studies are all DNA intercalators (Wang, 1985) , and since heat affects intercalator-induced changes in DNA supercoiling (Kampinga et al., 1988 (Kampinga et al., , 1989b , the reduced toxicity after heat may result from altered DNA intercalation of the drug. On the other hand, the effects could be due to a reduced accessibility of the topoisomerase II consensus sequences (= topoisomerase II cleavage sites). These sites are enriched in DNA found in close association with the nuclear matrix, called matrix-associated regions (MARs; Mirkovitch et al., 1984; Cockerill and Garrard, 1986; Darby et al., 1986; Gasser and Laemmli, 1986; Udvardy et al., 1986) . Hyperthermia has been shown to cause an insolubilisation (aggregation) of nuclear (matrix) proteins (for reviews see Laszlo, 1992; Kampinga, 1993) . This might reduce the accessibility of the topoisomerase II cleavage sites at the MARs and thereby the toxicity of topoisomerase II drugs after heat treatment. To distinguish between these possibilities, the interaction of heat and nonintercalating topoisomerase II drugs, VP16 and VM26, was studied in the current report.
Finally, the effect of thermotolerance on topoisomerase II drug toxicity was evaluated. First, elevated heat shock protein (hsp) expression, as found in thermotolerant cells, has been suggested to be responsible for resistance to topoisomerase II drugs. A mutant, heat-resistant cell line (3012) in which only hsc70 was elevated was found to be resistant to VM26 (Li, 1987) . Also, modulation of the levels of hsp27 in gene transfection expcriments showed a good correlation between hsp27 expression and doxorubicin resistance (Huot et al., 1991; Oesterreich et al., 1993 Determination of drug-induced DNA break formation Drug-induced break formation was measured by pulsed-field gelelectrophoresis (PFGE). This method, in the form of CHEF electrophoresis, detects DNA fragmentation on the basis of the formation of DNA double-strand breaks only and has been described in detail by Blocher and co-workers (Blocher et al., 1989; Blocher and Kunhi, 1990) . It was used with slight modification, applying image analysis-based fluorescent detection as described previously (Rosemann et al., 1993) . In short, cells were imbedded in agarose immediately after heat treatment and incubated with the drugs for 30 min at 37°C in 96-well microtitre plates. Thereafter, the cells were immediately lysed and treated with proteinase K and RNAse. CHEF electrophoresis (Bio-Rad) was carried out using 1% chromosomal grade agarose gels (Bio-Rad) using 75 min pulses at 40 V for 25 h. After the run, the DNA was stained with ethidium bromide. The fraction of DNA fragmented was determined by image analysis as described previously (Rosemann et al., 1993) .
Results
In a previous study (Kampinga et al., 1989a) , it was shown that preheating of both EAT and HeLa S3 cells led to a protection against the toxicity of the DNA-intercalating topoisomerase drug m-AMSA. This was confirmed in this study: both in the clonogenic assay ( Figure la immediately before the drug treatment reduced the killing efficacy of the drug. As can be seen in Figure 1 , a reduction in toxicity was also found for the non-intercalative topoisomerase II inhibitors VP16 and VM26. Heat-induced protection against drug toxicity was less for the nonintercalators than for m-AMSA ( Figure 1 ). As can be seen, the MTT and clonogenic assay yielded quite similar results and the extent of thermal protection was quite similar for both assays. Therefore, at least for these set of drugs, the more rapid and economic MTT assay can be used to study the combined effects of topoisomerase II drugs and heat.
HeLa S3 cells made thermotolerant by prior heating (15 min at 44°C and 5 h at 37'C) were found to have unaltered sensitivity to m-AMSA compared with nontolerant cells (Figure 2a) . In contrast, the thermotolerant cells were clearly more resistant to the non-intercalating topoisomerase II drug VP16 (Figure 2b) . A heat treatment for 15 min at 45°C immediately before drug treatment still had a significant protective effect on the sensitivity to both m-AMSA and VP16 in thermotolerant cells (Figure 2a and  b) . For m-AMSA the extent of this effect was similar to that observed in non-tolerant cells. For VP16, the protective effect of preheating on drug toxicity was somewhat less in thermotolerant cells.
The formation of cleavable complexes (detected as break formation after dissociation of the protein-drug-DNA interaction) has often been found to be related to drug toxicity of topoisomerase II drugs (Bakic et al., 1986; Glisson et al., 1986; Rowe et al., 1986; Covey et al., 1988) . Here, PFGE was used to detect double-strand breaks after the (Bakic et al., 1986; Glisson et al., 1986; Rowe et al., 1986; Covey et al., 1988) , it was found that, for the same concentrations, VM26 was far more potent than VP16 in inducing protein-associated breaks; m-AMSA showed an intermediate pattern ( Figure 3b ). As can be seen, this reflects the different toxicity of these drugs (Figure 3a) . Drug-induced break formation was attenuated in cells pretreated with heat; this was true for both m-AMSA and VP16 (Figure 4 ), in accordance with the protection seen at the level of cell survival. In thermotolerant cells, m-AMSA caused DNA fragmentation to the same extent as in control cells ( Figure Sa) , and heating the thermotolerant cells also reduced m-AMSA-induced DNA fragmentation, all again in parallel with the patterns seen at the survival level (Figure 2 ). For VP16, however, thermotolerant cells again showed DNA fragmentation patterns indistinguishable from non-tolerant cells (Figure 5b) , in contrast to their resistance to druginduced cell death (Figure 2b ). When heat preceded VP16 treatment, the same protection against drug-induced DNA fragmentation was found as in non-tolerant cells (Figures 4  and 5) . Thus, drug-induced DNA fragmentation and cell killing correlated in all cases except for the effect of thermotolerance on VP16 sensitivity (with no additional heat). seems relatively heat stable (Warters and Barrows, 1994) . In accordance with previous studies (Bakic et al., 1986; Glisson et al., 1986; Rowe et al., 1986; Covey et al., 1988; Kampinga et al., 1989a) , drug-induced break formation and cytotoxicity of topoisomerase II drugs were found to be related under all but one condition (see below). Hyperthermia before drug treatment decreases the number of cleavable complexes formed in proportion to the effects on drug toxicity. The heat protection action is thus related to reduced ability of the drugs to form cleavable complexes. As proposed before (Kampinga et al., 1989a) , the most likely explanation of this effect is a heat-induced change in the conformation of the topoisomerase II site, by decreasing the accessibility of either the topoisomerase II site for the topoisomerase 11-drug complex or the topoisomerase 1I-DNA complex for the drug. These interaction sites are known to be located at or near the control regions of active genes (Riou et al., 1986; Udvardy et al., 1986) and were found to be identical to the DNA sites (MARs) that are located at the nuclear matrix (Darby et al., 1986; Gasser and Laemmli, 1986; Mirkovitch et al., 1986; Pommier et al., 1991) . The MARs are thought to be important for the regulation of several DNA processes (Berezney, 1984) including replication, transcription and perhaps also repair. Thermal denaturation of (nuclear) proteins resulting in aggregation of usually soluble nuclear proteins (see Kampinga, 1993 , for review) with the (insoluble) nuclear matrix was found to correlate with the inhibitory effect of heat on m-AMSA toxicity (Kampinga et al., 1989a) . This aggregation also was found to be related to altered DNA-matrix attachment interactions (Warters et al., 1986; Sakkers et al., submitted) . In HeLa S3 cells, the initial aggregation is the same in thermotolerant cells as in non-tolerant cells (Kampinga et al., 1987 (Kampinga et al., , 1989c , consistent with the observation that thermal protection against drug toxicity and break formation is about the same in thermotolerant and non-tolerant cells (Figures 4  and 5) . The absence of a significant protective effect when heat is given after the VP16 and VM26 treatment (data not shown) is also in favour of an interrelationship between heat-induced decrement in MAR accessibility by protein aggregation and heat protection against drug toxicity: when the topoisomerase II-DNA complex has formed, heat cannot alter its toxicity any more and the treatments are additive in toxicity. Li (1987) and was speculated to be due to overexpression of hsp, hsc7O in particular. Yet others (Ciocca et al., 1992) also found that thermotolerance could result in resistance to intercalating topoisomerase II drugs such as doxorubicin. Moreover, different levels of hsp27 expression were found to be related to resistance to doxorubicin (Huot et al., 1991; Oesterreich et al., 1993) . So, whether the (non)intercalating character of the two drugs is the reason for the absence/presence of a protective mechanism operating in thermotolerant cells remains obscure. Another possibility may be found in the observation that the DNA cleavage pattern as a result of m-AMSA treatment was different from that seen after VP16 treatment (Pommier et al., 1991) . How this would affect the ability of thermotolerant cells (via elevated hsp levels?) to become resistant to VP16 but not m-AMSA is also as yet unclear. In any case, the observed resistance to VP16 was not accompanied by a reduced formation of cleavable complexes, as revealed by PFGE analysis (Figure 5 ). Li (1987) also observed no alterations in VM26-induced cleavable complex formation in thermotolerant cells. So neither drug accumulation nor drug-DNA interaction seems to be altered in the thermotolerant cells. This is also in accordance with hsp27-mediated protection against doxorubicin toxicity that was shown to be unrelated to reduced drug accumulation via a multidrug-like mechanism: immunoblot analysis revealed no P-gp 170 overexpression, and drug accumulation was unaltered by hsp27 overexpression (Huot et al., 1991) . So, as suggested by Li (1987) , the observed protection (by hsp) is likely to be at a later stage, e.g. in DNA damage processing. In relation to this, it is noteworthy that inducers of hsp27 phosphorylation alone already can lead to protection against, for example, doxorubicin and VM26 (Huot et al., 1992) . Hsp27 may exert phosphorylation-activated functions linked with growth signalling pathways , and as such elevated hsp27 expression and (de)phosphorylation may alter the cell cycle progression of the thermotolerant cells after drug treatment, allowing more time for DNA damage processing. The fact that growth arrest has been found to coincide with hsp27 phosphorylation and hsp27 levels (Spector et al., 1992) could be in accordance with this suggestion. Alternatively, druginduced apoptosis might be reduced in thermotolerant cells.
In conclusion, heating cells before topoisomerase II drug treatment protects against DNA break formation, leading to a reduced cytotoxicity of the drugs. In cancer therapy these treatments should therefore be used with caution. The data indicate that the hyperthermia treatment does reduce the ability of the drug-topoisomerase II complex to form the cleavable complexes related to drug toxicity. Protein aggregation induced by heat may explain such an effect. Elevated heat shock proteins may be related to the observed resistance of thermotolerant cells to VP16 (but not m-AMSA). This protective mechanism seems to occur at a stage after DNA-drug interaction.
Abbreviadons: m-AMSA, 4'-(9'-acrydinylamino)methanesulphon-maniside; VP16, etoposide; VM26, tenoposide; MAR, matrixassociated region; hsp, heat shock protein; hsc, heat shock cognate; dsb, double-strand break; PFGE, pulsed-field gelelectrophoresis.
